Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novartis Ag (NVS)

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 215,131,280
  • Shares Outstanding, K 2,291,800
  • Annual Sales, $ 53,166 M
  • Annual Income, $ 12,611 M
  • 60-Month Beta 0.59
  • Price/Sales 4.34
  • Price/Cash Flow 11.65
  • Price/Book 4.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.30
  • Number of Estimates 3
  • High Estimate 1.34
  • Low Estimate 1.21
  • Prior Year 1.24
  • Growth Rate Est. (year over year) +4.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.47 +0.43%
on 01/13/20
96.06 -2.28%
on 01/17/20
-0.95 (-1.00%)
since 12/24/19
3-Month
86.80 +8.15%
on 11/07/19
96.06 -2.28%
on 01/17/20
+6.63 (+7.60%)
since 10/24/19
52-Week
74.70 +25.67%
on 01/28/19
96.06 -2.28%
on 01/17/20
+17.87 (+23.51%)
since 01/24/19

Most Recent Stories

More News
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU

J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.

MRK : 85.98 (-2.91%)
PFE : 39.82 (-2.19%)
AZN : 49.28 (-1.83%)
RHHBY : 41.2000 (-2.81%)
GSK : 47.23 (-1.23%)
JNJ : 148.32 (-0.14%)
NVS : 93.87 (-1.11%)
Global Epilepsy Therapeutics Market 2020 – Abbott Laboratories , GlaxoSmithKline plc , Cephalon , Johnson & Johnson , Pfizer

ABT : 90.40 (-0.36%)
GSK : 47.23 (-1.23%)
NVS : 93.87 (-1.11%)
VRX.TO : 30.80 (-3.33%)
Future Outlook on Ophthalmic Devices Market Key Players, Supply Chain and Analysis, Application, Market Drivers, Restraints, In-Depth Analysis, forecast to 2026

A new market research report by Big Market Research on reveals that the market is estimated to grow with a substantial growth rate from 2019-2026. This report is a valuable document for major players...

CZMWF : 132.2000 (-0.97%)
GKOS : 57.65 (+0.07%)
HOCPF : 102.0000 (+4.08%)
NVS : 93.87 (-1.11%)
STAA : 38.64 (-6.98%)
TOPCF : 15.1800 (+0.08%)
VRX.TO : 30.80 (-3.33%)
Eye Health Ingredients Market 2020-2029 | Modern Analysis of Worldwide Competition, Strategic Development and Progressive Approach

A recent market research analysis titled, Eye Health Ingredients Market offers insightful information to the clients escalating their basic leadership size explores distinct significant facets associated...

BASFY : 17.5000 (-0.46%)
FMC : 95.68 (-1.19%)
NVS : 93.87 (-1.11%)
VRX.TO : 30.80 (-3.33%)
Vision Care Market is expected to grow at a CAGR of 9.7% during the forecast period 2016-2026

Future Market Insights delivers key insights on the in a new publication titled "". Vision care is a billion dollar market accounting for a substantial proportion of worldwide healthcare expenditure....

NVS : 93.87 (-1.11%)
VRX.TO : 30.80 (-3.33%)
Ocular Inflammation Treatment Market With Top Countries Data : Global Industry Trends, Market Size, Growth, Segmentation, Future Demands, Latest Innovation, Sales Revenue by Regional Forecast to 2025

A recent report provides crucial insights along with application based and forecast information in the Global Ocular Inflammation Treatment Market. The report provides a comprehensive analysis of key factors...

AKRX : 1.31 (-3.68%)
ALIM : 7.54 (+1.89%)
AGN : 188.19 (-1.26%)
NVS : 93.87 (-1.11%)
PFE : 39.82 (-2.19%)
VRX.TO : 30.80 (-3.33%)
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

NVS : 93.87 (-1.11%)
AVDL : 6.89 (-8.50%)
JAZZ : 145.74 (-2.25%)
TEVA : 10.10 (-2.79%)
Roche's Risdiplam Meets Primary Endpoint in Infants Study

Roche's (RHHBY) risdiplam meets primary endpoint in FIREFISH study in infants with type 1 spinal muscular atrophy.

RHHBY : 41.2000 (-2.81%)
NVS : 93.87 (-1.11%)
BIIB : 278.14 (-2.14%)
PTCT : 51.92 (-2.64%)
Ophthalmic Therapeutic Drugs Market With Top Countries Data : Global Industry Trends, Market Size, Growth, Segmentation, Future Demands, Latest Innovation, Sales Revenue by Regional Forecast to 2025

A recent report provides crucial insights along with application based and forecast information in the The report provides a comprehensive analysis of key factors that are expected to drive the growth...

AERI : 21.50 (-4.70%)
AGN : 188.19 (-1.26%)
NVS : 93.87 (-1.11%)
REGN : 345.28 (-3.17%)
VRX.TO : 30.80 (-3.33%)
Ophthalmic Devices Market 2019-2026 Segmentation along with Regional Outlook, Competitive Strategies, Factors Contributing to Growth and Forecast

A new market research report by Big Market Research on reveals that the market is estimated to grow with a substantial growth rate from 2019-2026. This report is a valuable document for major players...

CZMWF : 132.2000 (-0.97%)
GKOS : 57.65 (+0.07%)
HOCPF : 102.0000 (+4.08%)
NVS : 93.87 (-1.11%)
STAA : 38.64 (-6.98%)
TOPCF : 15.1800 (+0.08%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 95.80
1st Resistance Point 94.84
Last Price 93.87
1st Support Level 93.28
2nd Support Level 92.68

See More

52-Week High 96.06
Last Price 93.87
Fibonacci 61.8% 87.90
Fibonacci 50% 85.38
Fibonacci 38.2% 82.86
52-Week Low 74.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar